中华放射医学与防护杂志
中華放射醫學與防護雜誌
중화방사의학여방호잡지
Chinese Journal of Radiological Medicine and Protection
2012年
5期
498-501
,共4页
陈海霞%金风%吴伟莉%甘家应%李媛媛
陳海霞%金風%吳偉莉%甘傢應%李媛媛
진해하%금풍%오위리%감가응%리원원
鼻咽癌%调强放疗%时间调节化疗
鼻嚥癌%調彊放療%時間調節化療
비인암%조강방료%시간조절화료
Nasopharyngeal carcinoma%Intensity-modulated radiotherapy%Chronomodulated chemotherapy
目的 探讨顺铂+氟尿嘧啶(PF)方案时间调节化疗诱导加同期调强放疗(IMRT)治疗鼻咽癌的临床疗效.方法 回顾性分析48例初治鼻咽癌患者行PF方案时间调节化疗诱导联合同期放化疗的疗效.将鼻咽和颈部的靶体积划分为鼻咽大体肿瘤体积(GTVnx)、颈部大体肿瘤体积(GTVnd)、临床靶体积1(CTV1)和临床靶体积2(CTV2).GTVnx、GTVnd、CTV1、CTV2处方剂量分别73.92 ~ 77.88、69.96、60.06 ~ 66.00、50.96 ~ 56.00 Gy,采用传统照射分割方式.采用Kaplan-Meier法进行生存分析.RTOG/EORTC标准评价急性反应和晚期损伤.结果 完全缓解(CR)20例,占41.6%,部分缓解(PR)23例,占47.9%,稳定(SD)2例,占4.2%.肿瘤局部控制率为89.6%,1、2、4年的生存率分别是93.8%、79.2%、64.5%.多数患者仅表现为1~2级急性反应和0~1级晚期损伤,未观察到4级急性反应和晚期损伤.剂量体积分布直方图(DVH)分析显示IMRT提高了靶体积照射总剂量和分次剂量,减少了危及器官受照总剂量和分次剂量.结论 PF方案时间调节化疗诱导加同期配合IMRT是鼻咽癌安全的治疗方案.
目的 探討順鉑+氟尿嘧啶(PF)方案時間調節化療誘導加同期調彊放療(IMRT)治療鼻嚥癌的臨床療效.方法 迴顧性分析48例初治鼻嚥癌患者行PF方案時間調節化療誘導聯閤同期放化療的療效.將鼻嚥和頸部的靶體積劃分為鼻嚥大體腫瘤體積(GTVnx)、頸部大體腫瘤體積(GTVnd)、臨床靶體積1(CTV1)和臨床靶體積2(CTV2).GTVnx、GTVnd、CTV1、CTV2處方劑量分彆73.92 ~ 77.88、69.96、60.06 ~ 66.00、50.96 ~ 56.00 Gy,採用傳統照射分割方式.採用Kaplan-Meier法進行生存分析.RTOG/EORTC標準評價急性反應和晚期損傷.結果 完全緩解(CR)20例,佔41.6%,部分緩解(PR)23例,佔47.9%,穩定(SD)2例,佔4.2%.腫瘤跼部控製率為89.6%,1、2、4年的生存率分彆是93.8%、79.2%、64.5%.多數患者僅錶現為1~2級急性反應和0~1級晚期損傷,未觀察到4級急性反應和晚期損傷.劑量體積分佈直方圖(DVH)分析顯示IMRT提高瞭靶體積照射總劑量和分次劑量,減少瞭危及器官受照總劑量和分次劑量.結論 PF方案時間調節化療誘導加同期配閤IMRT是鼻嚥癌安全的治療方案.
목적 탐토순박+불뇨밀정(PF)방안시간조절화료유도가동기조강방료(IMRT)치료비인암적림상료효.방법 회고성분석48례초치비인암환자행PF방안시간조절화료유도연합동기방화료적료효.장비인화경부적파체적화분위비인대체종류체적(GTVnx)、경부대체종류체적(GTVnd)、림상파체적1(CTV1)화림상파체적2(CTV2).GTVnx、GTVnd、CTV1、CTV2처방제량분별73.92 ~ 77.88、69.96、60.06 ~ 66.00、50.96 ~ 56.00 Gy,채용전통조사분할방식.채용Kaplan-Meier법진행생존분석.RTOG/EORTC표준평개급성반응화만기손상.결과 완전완해(CR)20례,점41.6%,부분완해(PR)23례,점47.9%,은정(SD)2례,점4.2%.종류국부공제솔위89.6%,1、2、4년적생존솔분별시93.8%、79.2%、64.5%.다수환자부표현위1~2급급성반응화0~1급만기손상,미관찰도4급급성반응화만기손상.제량체적분포직방도(DVH)분석현시IMRT제고료파체적조사총제량화분차제량,감소료위급기관수조총제량화분차제량.결론 PF방안시간조절화료유도가동기배합IMRT시비인암안전적치료방안.
Objective To evaluate the therapeutic effects,acute and late side-effects of cisplatin plus 5-fluorouracil (PF) schemed chronomodulated chemotherapy combined with concurrent intensitymodulated radiotherapy(IMRT) for nasopharyngeal carcinoma.Methods A total of 48 nasopharyngeal carcinoma patients treated with chronomodulated chemotherapy plus concurrent IMRT were retrospectively studied.The radiation doses prescribed to the gross target volume GTVnx of nasopharyngeal,to the positive neck lymphnodes GTVnd,to the clinical target volume CTV1,and to CTV2 were 73.92-77.88,69.96,60.06-66.00 and 50.96-56.00 Gy respectively.The Kaplan-Meier survival analysis was used to calculate the local-regional progression-free rate.The acute and late side-effects were graded according to RTOG radiation morbidity scoring criteria.Results The complete remission (CR) rate was 41.6%(20/48) ; the partial remission (PR) rate was 47.9% (23/48) ; the stable disease (SD) rate was 4.2%(2/48) ; and the local tumor control rate was 89.6%.Most of the patients had grade 1 to 2 acute side effects and grade 0 to 1 late side-effects.No grade 4 acute and late toxicity was observed.1,2,4-year survival rates were 93.8%,79.2% and 64.5%,respectively.The DVH analysis showed that IMRT improved the total dose and dose per-fraction to the target volume with considerable dose reduction of the normal structures at the same time.Conclusions PF chronomodulated chemotherapy plus concurrent intensity-modulated radiotherapy for NPC could improve therapeutic effects with satisfactory tolerance of the side effects.